These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Topiramate and the risk of urolithiasis. Hanchanale VS; Biyani CS; Browning AJ; Joyce AD BJU Int; 2011 Feb; 107(3):352-4. PubMed ID: 21265983 [No Abstract] [Full Text] [Related]
5. Topiramate and metabolic acidosis: an evolving story. Gupta S; Gao JJ; Emmett M; Fenves AZ Hosp Pract (1995); 2017 Dec; 45(5):192-195. PubMed ID: 28828886 [TBL] [Abstract][Full Text] [Related]
6. [Potomania as a side-effect of topiramate]. Alda M; García Campayo J; Cerdán C; Laguna C Med Clin (Barc); 2007 Mar; 128(10):397-8. PubMed ID: 17386248 [No Abstract] [Full Text] [Related]
15. Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. Winum JY; Temperini C; El Cheikh K; Innocenti A; Vullo D; Ciattini S; Montero JL; Scozzafava A; Supuran CT J Med Chem; 2006 Nov; 49(24):7024-31. PubMed ID: 17125255 [TBL] [Abstract][Full Text] [Related]
16. Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives. Maryanoff BE; Costanzo MJ; Nortey SO; Greco MN; Shank RP; Schupsky JJ; Ortegon MP; Vaught JL J Med Chem; 1998 Apr; 41(8):1315-43. PubMed ID: 9548821 [TBL] [Abstract][Full Text] [Related]
17. Topiramate increases biochemical risk of nephrolithiasis. Lamb EJ; Stevens PE; Nashef L Ann Clin Biochem; 2004 Mar; 41(Pt 2):166-9. PubMed ID: 15025812 [TBL] [Abstract][Full Text] [Related]
18. Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Celebisoy N; Gökçay F; Sirin H; Akyürekli O Acta Neurol Scand; 2007 Nov; 116(5):322-7. PubMed ID: 17922725 [TBL] [Abstract][Full Text] [Related]
19. Topiramate for headaches. Evans RW; Young WB Headache; 2001 Sep; 41(8):833-5. PubMed ID: 11576212 [No Abstract] [Full Text] [Related]
20. The first example of a significant active site conformational rearrangement in a carbonic anhydrase-inhibitor adduct: the carbonic anhydrase I-topiramate complex. Alterio V; Monti SM; Truppo E; Pedone C; Supuran CT; De Simone G Org Biomol Chem; 2010 Aug; 8(15):3528-33. PubMed ID: 20505865 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]